TLDR
- SELLAS shares plunge 18.84% as a discounted $150M stock offering hits sentiment.
- SLS prices 11.54 million new shares at $13 each to raise $150 million gross.
- Underwriters secure an option to buy 1.73 million additional SELLAS shares.
- SELLAS expects its $150 million public stock offering to close on November 20, 2026.
- New shares could dilute existing holders as SELLAS raises funds for operations.
SELLAS Life Sciences Group (SLS) shares plunged 18.84% to $14.56, losing $3.39 amid heavy selling pressure. The decline followed the company’s announcement of a $150 million public stock offering priced below its recent trading levels. The transaction will raise additional capital for the cancer drug developer while increasing its outstanding share count.
SELLAS Life Sciences Group, Inc., SLS
SELLAS Life Sciences Prices $150 Million Stock Offering
SELLAS announced plans to sell 11,538,462 common shares at $13.00 each through an underwritten public offering. The transaction targets $150 million in gross proceeds before underwriting commissions and other related expenses. Moreover, the offering price represents a discount to the company’s reported share price following the announcement.
The company also granted underwriters a 30-day option to acquire another 1,730,769 common shares. This provision could increase the offering’s total proceeds if underwriters exercise their purchase rights. Meanwhile, SELLAS expects to complete the transaction on November 20, 2026, subject to customary closing conditions.
J.P. Morgan and TD Cowen serve as lead book-running managers for the public offering. Mizuho also participates as a book-running manager, supporting the transaction alongside other financial institutions. Additionally, A.G.P./Alliance Global Partners and Maxim Group LLC act as lead managers for the offering.
SLS Stock Faces Pressure From Share Dilution
The discounted share sale introduces additional equity into the market and expands the company’s outstanding shares. Consequently, existing shareholders face dilution as SELLAS issues new stock to raise capital. The offering also provides the company with substantial funding through the public equity market.
SELLAS operates as a late-stage clinical biopharmaceutical company focused on developing cancer treatments. Its research programs target several cancer indications through therapies under clinical development. Therefore, access to additional capital remains important for supporting research activities and advancing its development pipeline.
Biotechnology companies frequently use equity offerings to finance clinical trials and other operating requirements. However, issuing additional shares can reduce existing shareholders’ proportional ownership of a company. In this case, the discounted offering coincided with a sharp decline in SLS shares.
SELLAS Advances Offering Under SEC Registration
SELLAS will conduct the offering under its existing Form S-3 shelf registration statement. The company filed the registration with the Securities and Exchange Commission on March 20, 2026. The registration became effective automatically upon filing, allowing SELLAS to pursue securities offerings under the applicable framework.
The company has already filed a preliminary prospectus supplement outlining the transaction’s terms. SELLAS plans to submit a final supplement containing the offering’s complete details. The SEC website will provide access to these documents for public review.
The company expects the transaction to close after completing the required procedures and satisfying customary conditions. Once completed, the offering will strengthen SELLAS’ cash resources while expanding its common share base. The financing marks another capital-raising step as SELLAS continues developing its cancer treatment portfolio.





